Systemic Vasculitis: Clinical Trials

16 trials for Systemic Vasculitis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

16 completed. 16 Phase 1, 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 116Completed 16
Phase 24Completed 4

Follow Systemic Vasculitis: new trials by email Literature Review of Systemic Vasculitis trials Research Report on Systemic Vasculitis

Trials (filtered) newest first · largest first

All 16 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
The Safety and Tolerability of STSA-1002 Following Subcutaneous Injection in Healthy Subjects
STSA-1002 subcutaneous injection - Antineutrophil Cytoplasmic Antibody Associated Vasculitis
Phase 1CompletedStaidson (Beijing) Biopharmaceuticals Co., Ltd202023-01-312023-05-26
Efficacy and Safety of Substitution of Glucocorticoid for BDB-001 Injection in Patients With Anti-neutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis
BDB-001 injection, Cyclophosphamide, Glucocorticoids - ANCA-associated Vasculitis
Phase 1 / Phase 2CompletedStaidson (Beijing) Biopharmaceuticals Co., Ltd932022-02-222025-08-07
A Study to Assess the Effect of Avacopan at Therapeutic and Supratherapeutic Doses on the QT/QTc Interval in Healthy Participants
Avacopan, Moxifloxacin, Placebo for avacopan - Electrocardiography
Phase 1CompletedAmgen582019-11-082023-08-14
A Study to Evaluate the Pharmacokinetics of Avacopan (CCX168) in Participants With Mild or Moderate Hepatic Impairment
Avacopan - Hepatic Impairment
Phase 1CompletedAmgen242018-04-172023-08-22
A Study of CCX168 in Japanese and Caucasian Healthy Adult Males
CCX168, Placebo - Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
Phase 1CompletedAmgen802017-10-232023-08-14
A Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant Medications
CCX168, Midazolam, Celecoxib - Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
Phase 1CompletedAmgen322016-01-142023-08-22
A Study in Healthy Volunteers to Evaluate the Pharmacokinetic Food Effect and Cardiac Safety of CCX168
CCX168 - Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
Phase 1CompletedAmgen162015-12-032023-08-14
A Study to Assess the Mass Balance Recovery (Absorption, Distribution, Metabolism and Excretion) of [14C]CCX168 in Healthy Participants
[14C]CCX168 - Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
Phase 1CompletedAmgen62014-10-202023-08-22
Abatacept in Treating Adults With Mild Relapsing Wegener's Granulomatosis
Abatacept - Wegener's Granulomatosis
Phase 1 / Phase 2CompletedUniversity of Pennsylvania202008-02-012016-01-18
Mepolizumab As a Steroid-sparing Treatment Option in the Churg Strauss Syndrome
Mepolizumab - Churg Strauss Syndrome
Phase 1 / Phase 2CompletedBrigham and Women's Hospital102007-09-012017-03-22
An Open Label Pilot Study Examining the Use of Rituximab in Patients With Wegener's Granulomatosis Who Have Experienced Disease Relapse on Standard Therapies
Rituximab - Wegener's Granulomatosis
Phase 1CompletedNational Institute of Allergy and Infectious Diseases (NIAID)102003-10-012008-03-04
CellCept in p-ANCA Vasculitis
CellCept (mycophenolate mofetil) - MPO-ANCA Vasculitis, Microscopic Polyangiitis
Phase 1CompletedMayo Clinic182002-12-012011-03-23
Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome
Mepolizumab - Hypereosinophilic Syndromes, Eosinophilic Gastroenteritis
Phase 1 / Phase 2CompletedChildren's Hospital Medical Center, Cincinnati242001-12-012020-07-29
Mycophenolate Mofetil to Treat Wegener's Granulomatosis and Related Vascular Inflammatory Conditions
Mycophenolate Mofetil - Vasculitis, Wegener's Granulomatosis
Phase 1CompletedNational Institute of Allergy and Infectious Diseases (NIAID)501998-04-012008-03-04
Phase I Trial of Recombinant Human Interleukin-10 (SCH 52000) in Patients With Wegener's Granulomatosis
Interleukin-10 - Vasculitis, Wegener's Granulomatosis
Phase 1CompletedNational Institute of Allergy and Infectious Diseases (NIAID)151998-02-012008-03-04
Diagnostic Effectiveness of Virtual Bronchoscopy
virtual bronchoscopy - Bronchogenic Carcinoma, Chronic Granulomatous Disease
Phase 1CompletedNational Institutes of Health Clinical Center (CC)1201995-12-012008-03-04

Narrower conditions

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (8)  ·  Vasculitis (8)  ·  Granulomatosis with Polyangiitis (5)  ·  Vascular Diseases (3)  ·  Cardiovascular Diseases (2)  ·  Churg-Strauss Syndrome (2)  ·  Atypical Hemolytic Uremic Syndrome (1)  ·  Autoimmune Diseases (1)  ·  Carcinoma, Bronchogenic (1)  ·  Eosinophilic Esophagitis (1)  ·  Eosinophilic enteropathy (1)  ·  Glomerulonephritis, IGA (1)  ·  Granulomatous Disease, Chronic (1)  ·  Hypereosinophilic Syndrome (1)  ·  Inflammation (1)

Broader conditions

Immune System Diseases (16)  ·  Skin Diseases (16)  ·  Skin Diseases, Vascular (16)  ·  Skin and Connective Tissue Diseases (16)  ·  Autoimmune Diseases (15)  ·  Cardiovascular Diseases (14)  ·  Vascular Diseases (13)  ·  Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (8)  ·  Vasculitis (8)  ·  Lung Diseases (5)  ·  Lung Diseases, Interstitial (5)  ·  Respiratory Tract Diseases (5)  ·  Hemic and Lymphatic Diseases (4)  ·  Hematologic Diseases (3)

Interventions

avacopan (5)  ·  Mycophenolic Acid (2)  ·  mepolizumab (2)  ·  Abatacept (1)  ·  BDB001 (1)  ·  Celecoxib (1)  ·  Cyclophosphamide (1)  ·  Glucocorticoids (1)  ·  Interleukin-10 (1)  ·  Itraconazole (1)  ·  Midazolam (1)  ·  Moxifloxacin (1)  ·  Prednisone (1)  ·  Rifampin (1)  ·  Rituximab (1)

Sponsors

Amgen (6)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (3)  ·  Staidson (Beijing) Biopharmaceuticals Co., Ltd (2)  ·  Brigham and Women's Hospital (1)  ·  Children's Hospital Medical Center, Cincinnati (1)  ·  Mayo Clinic (1)  ·  National Institutes of Health Clinical Center (CC) (1)  ·  University of Pennsylvania (1)

Countries

United States (14)  ·  China (1)  ·  Japan (1)

Top investigators

Carol A. Langford, MD, MHS (1)  ·  Fernando C. Fervenza, M.D., Ph.D. (1)  ·  Marc E. Rothenberg, MD (1)  ·  Martin K Kankam, Doctor (1)  ·  Michael Wechsler, MD (1)  ·  Minghui Zhao, Postdoc (1)  ·  Peter A. Merkel, MD, MPH (1)

Results publications

PMID 20093349, PMID 24323392, PMID 38973157, PMID 38993026

NIH funding

U54AR057319 (1)